Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2021 Aug 2

PMID 34333981

Citations 12

Authors

David H Drewry

Joel K Annor-Gyamfi

Carrow I Wells

Julie E Pickett

Verena Dederer

Franziska Preuss

Sebastian Mathea

Alison D Axtman

Affiliations

Soon will be listed here.

Abstract

The pyrimidine core has been utilized extensively to construct kinase inhibitors, including eight FDA-approved drugs. Because the pyrimidine hinge-binding motif is accommodated by many human kinases, kinome-wide selectivity of resultant molecules can be poor. This liability was seen as an advantage since it is well tolerated by many understudied kinases. We hypothesized that nonexemplified aminopyrimidines bearing side chains from well-annotated pyrimidine-based inhibitors with off-target activity on understudied kinases would provide us with useful inhibitors of these lesser studied kinases. Our strategy paired mixing and matching the side chains from the 2- and 4-positions of the parent compounds with modifications at the 5-position of the pyrimidine core, which is situated near the gatekeeper residue of the binding pocket. Utilizing this approach, we imparted improved kinome-wide selectivity to most members of the resultant library. Importantly, we also identified potent biochemical and cell-active lead compounds for understudied kinases like DRAK1, BMP2K, and MARK3/4.

Citing Articles

System biology-based assessment of the molecular mechanism of IMPHY000797 in Parkinson's disease: a network pharmacology and in-silico evaluation.

Subramanian G, Fanai H, Chand J, Ahmad S, Attia S, Emran T Sci Rep. 2024; 14(1):23414.

PMID: 39379677 PMC: 11461797. DOI: 10.1038/s41598-024-75603-x.

Role of CSF1R 550th-tryptophan in kusunokinin and CSF1R inhibitor binding and ligand-induced structural effect.

Chompunud Na Ayudhya C, Graidist P, Tipmanee V Sci Rep. 2024; 14(1):12531.

PMID: 38822100 PMC: 11143223. DOI: 10.1038/s41598-024-63505-x.

Illuminating the druggable genome: Pathways to progress.

Sharma K, Colvis C, Rodgers G, Sheeley D Drug Discov Today. 2023; 29(3):103805.

PMID: 37890715 PMC: 10939933. DOI: 10.1016/j.drudis.2023.103805.

Extract2Chip-Bypassing Protein Purification in Drug Discovery Using Surface Plasmon Resonance.

Paiva A, Lemos A, Busse P, Martins M, Silva D, Freitas M Biosensors (Basel). 2023; 13(10).

PMID: 37887106 PMC: 10605449. DOI: 10.3390/bios13100913.

Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology.

Castano A, Silvestre M, Wells C, Sanderson J, Ferrer C, Ong H Elife. 2023; 12.

PMID: 37490324 PMC: 10406435. DOI: 10.7554/eLife.88206.

References

Stathias V, Turner J, Koleti A, Vidovic D, Cooper D, Fazel-Najafabadi M . LINCS Data Portal 2.0: next generation access point for perturbation-response signatures. Nucleic Acids Res. 2019; 48(D1):D431-D439. PMC: 7145650. DOI: 10.1093/nar/gkz1023. View

Drewry D, Wells C, Andrews D, Angell R, Al-Ali H, Axtman A . Progress towards a public chemogenomic set for protein kinases and a call for contributions. PLoS One. 2017; 12(8):e0181585. PMC: 5540273. DOI: 10.1371/journal.pone.0181585. View

Fensome A, Ambler C, Arnold E, Banker M, Brown M, Chrencik J . Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018; 61(19):8597-8612. DOI: 10.1021/acs.jmedchem.8b00917. View

Lasagna-Reeves C, de Haro M, Hao S, Park J, Rousseaux M, Al-Ramahi I . Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model. Neuron. 2016; 92(2):407-418. PMC: 5745060. DOI: 10.1016/j.neuron.2016.09.022. View

Berginski M, Moret N, Liu C, Goldfarb D, Sorger P, Gomez S . The Dark Kinase Knowledgebase: an online compendium of knowledge and experimental results of understudied kinases. Nucleic Acids Res. 2020; 49(D1):D529-D535. PMC: 7778917. DOI: 10.1093/nar/gkaa853. View

Metz K, Deoudes E, Berginski M, Jimenez-Ruiz I, Aksoy B, Hammerbacher J . Coral: Clear and Customizable Visualization of Human Kinome Data. Cell Syst. 2018; 7(3):347-350.e1. PMC: 6366324. DOI: 10.1016/j.cels.2018.07.001. View

Oakes J, Davies M, Collins M . TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol Brain. 2017; 10(1):5. PMC: 5288885. DOI: 10.1186/s13041-017-0287-x. View

Wells C, Drewry D, Pickett J, Tjaden A, Kramer A, Muller S . Development of a potent and selective chemical probe for the pleiotropic kinase CK2. Cell Chem Biol. 2021; 28(4):546-558.e10. PMC: 8864761. DOI: 10.1016/j.chembiol.2020.12.013. View

Roskoski Jr R . Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res. 2019; 152:104609. DOI: 10.1016/j.phrs.2019.104609. View

10.

Thomson D, Poeckel D, Zinn N, Rau C, Strohmer K, Wagner A . Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor. ACS Med Chem Lett. 2019; 10(5):780-785. PMC: 6512007. DOI: 10.1021/acsmedchemlett.9b00027. View

11.

Wojdyla J, Kaminski J, Panepucci E, Ebner S, Wang X, Gabadinho J . DA+ data acquisition and analysis software at the Swiss Light Source macromolecular crystallography beamlines. J Synchrotron Radiat. 2017; 25(Pt 1):293-303. PMC: 5741135. DOI: 10.1107/S1600577517014503. View

12.

Murphy J, Korzhnev D, Ceccarelli D, Briant D, Zarrine-Afsar A, Sicheri F . Conformational instability of the MARK3 UBA domain compromises ubiquitin recognition and promotes interaction with the adjacent kinase domain. Proc Natl Acad Sci U S A. 2007; 104(36):14336-41. PMC: 1964837. DOI: 10.1073/pnas.0703012104. View

13.

McCoy A, Grosse-Kunstleve R, Storoni L, Read R . Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 4):458-64. DOI: 10.1107/S0907444905001617. View

14.

Feldman R, Wu J, Polokoff M, Kochanny M, Dinter H, Zhu D . Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005; 280(20):19867-74. DOI: 10.1074/jbc.M501367200. View

15.

Drewes G, Ebneth A, Preuss U, Mandelkow E, Mandelkow E . MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997; 89(2):297-308. DOI: 10.1016/s0092-8674(00)80208-1. View

16.

Faisal M, Kim J, Yoo K, Roh E, Hong S, Lee S . Development and Therapeutic Potential of NUAKs Inhibitors. J Med Chem. 2020; 64(1):2-25. DOI: 10.1021/acs.jmedchem.0c00533. View

17.

Crew A, Raina K, Dong H, Qian Y, Wang J, Vigil D . Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. J Med Chem. 2017; 61(2):583-598. DOI: 10.1021/acs.jmedchem.7b00635. View

18.

McIver E, Bryans J, Birchall K, Chugh J, Drake T, Lewis S . Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases. Bioorg Med Chem Lett. 2012; 22(23):7169-73. DOI: 10.1016/j.bmcl.2012.09.063. View

19.

Llona-Minguez S, Baiget J, Mackay S . Small-molecule inhibitors of IκB kinase (IKK) and IKK-related kinases. Pharm Pat Anal. 2013; 2(4):481-98. DOI: 10.4155/ppa.13.31. View

20.

Wells C, Counago R, Limas J, Almeida T, Cook J, Drewry D . SGC-AAK1-1: A Chemical Probe Targeting AAK1 and BMP2K. ACS Med Chem Lett. 2020; 11(3):340-345. PMC: 7073879. DOI: 10.1021/acsmedchemlett.9b00399. View